An 8-week Multi-center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension

NCT00219180 Phase 3 COMPLETED

To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension

Details

Lead sponsor	Novartis
Phase	Phase 3
Status	COMPLETED
Enrolment	1797
Start date	2005-06
Completion	2006-09

Conditions

• Hypertension

Interventions

• aliskiren

Primary outcomes

• Change from baseline in diastolic blood pressure after week 8

Countries

United States, Germany